An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 8, 2011, Pages 975-983

  Rollins Raval, Marian ^a   Chivukula, Mamatha ^a   Tseng, George C ^b   Jukic, Drazen ^a,c   Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PREDICTIVE VALUE; REVIEW; SKIN TUMOR; SWEAT GLAND TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; SWEAT GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80051954171     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/2009-0445-OAR2     Document Type: Review

References (29)

1. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. South Med J. 2003;96(2): 164-167. (Pubitemid 36268589)
2. Spencer PS, Helm TN. Skin metastases in cancer patients. Cutis. 1987, 39(2): 119-121. (Pubitemid 17011376)
3. Cooper PH. Carcinomas of sweat glands. Pathol Annu. 1987;22(pt1): 83-124.
4. Cangelosi JJ, Nash JW, Prieto VG, Ivan D. Cutaneous adnexal tumor with an unusual presentation-discussion of a potential diagnostic pitfall. Am J Dermatopathol. 2009;31 (3):278-281.
5. McLean SR, Shousha S, Francis N, et al. Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. I Cutan Pathol. 2007;34(12):934-938. (Pubitemid 350132003)
6. Bayer-Garner IB, Smoller B. Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site. Mod Pathol. 2000;13(2):119-122. (Pubitemid 30109097)
7. Riva C, Dainese E, Caprara G, et al. Immunohistochemical study of androgen receptors in breast carcinoma: evidence of their frequent expression in lobular carcinoma. Virchows Arch. 2005;447(4):695-700. (Pubitemid 41571184)
8. Narita D, Raica M, Suciu C, Cimpean A, Anghel A. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol. 2006;44(3):165-172. (Pubitemid 44131983)
9. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003;98(4):703-711. (Pubitemid 36959265)
10. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol. 2004, 28(11): 1506-1512. (Pubitemid 39425518)
11. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127(1):103-113. (Pubitemid 46797025)
12. Smith KJ, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25(4):464-471. (Pubitemid 32240885)
13. Kariya Y, Moriya T, Suzuki T, et al. Sex steroid hormone receptors in human skin appendage and its neoplasms. Endocr J. 2005;52(3):317-325. (Pubitemid 41003523)
14. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008; 21(2):178-185. (Pubitemid 351172169)
15. Hiatt KM, Pillow JL, Smoller BR. Her-2 expression in cutaneous eccrine and apocrine neoplasms. Mod Pathol. 2004;17(1):28-32. (Pubitemid 41656449)
16. Wallace ML, Longacre TA, Smoller BR. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol. 1995;8(9): 897-901. (Pubitemid 26025965)
17. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands: a histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998, 109(1):75-84. (Pubitemid 28023814)
18. Busam KJ, Tan LK, Granter SR, et al. Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol. 1999; 12(8):786-793. (Pubitemid 29383882)
19. Plumb SJ, Argenyi ZB, Stone MS, De Young BR. Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma. Am J Dermatopathol. 2004;26(6):447-451. (Pubitemid 40082507)
20. Qureshi HS, Ormsby AH, Lee MW, Zarbo RJ, Ma CK. The diagnostic utility of p63, CK5/6, CK 7, and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. I Cutan Pathol. 2004;31(2):145-152. (Pubitemid 38130424)
21. Ivan D, Nash JW, Prieto VG, et al. Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. I Cutan Pathol. 2007;34(6):474-480. (Pubitemid 46791198)
22. Ivan D, Hafeez Diwan A, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18(1):137-142. (Pubitemid 40128106)
23. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol. 2007;31(2):304-310. (Pubitemid 46175033)
24. Ormsby AH, Snow JL, Su WP, Goellner JR. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. I Am Acad Dermatol. 1995;32(5, pt 1):711-716.
25. Bhargava R, Beriwal S, McManus K, Dabbs DJ. CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. Am I Clin Pathol. 2008;130(5):724-730.
26. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006; 19(11):1506-1511. (Pubitemid 44624171)
27. Feldman AL, Dogan A. Diagnostic uses of Pax5 immunohistochemistry. Adv Anat Pathol. 2007;14(5):323-334. (Pubitemid 47312287)
28. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol. 2007;60(6):709-714. (Pubitemid 46975231)
29. Carlsten JR, Lewis MD, Saddler K, et al. Spiradenocylindrocarcinoma: a malignant hybrid tumor. J Cutan Pathol. 2005;32(2):166-171. (Pubitemid 40216055)